The aim of the present study was to investigate differences between the mTOR targets S6K1 and S6K2 and their individual potentials as new clinical targets in breast cancer, as well as further explore the importance of the S6K2/4EBP1 co-expression. This evidence concerns the gene RPS6KB1 and breast cancer.